Adipose Stromal Vascular Fraction-Mediated Improvements at Late-Stage Disease in a Murine Model of Multiple Sclerosis

Stem Cells

Volumn 35, Issue 2, 2017, Pages 532-544

  Bowles, Annie C ^a,b   Strong, Amy L ^a   Wise, Rachel M ^a,b   Thomas, Robert C ^b   Gerstein, Brittany Y ^b   Dutreil, Maria F ^a   Hunter, Ryan S ^a   Gimble, Jeffrey M ^a,c   Bunnell, Bruce A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tulane University   (United States)

^c LaCell LLC   (United States)

Author keywords

Adipose; Experimental autoimmune encephalomyelitis; Immunomodulation; Multiple sclerosis; Stromal vascular fraction

Indexed keywords

ARGINASE 1; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE; PLASMA PROTEIN;

ADIPOCYTE; ADIPOSE DERIVED STEM CELL; ADIPOSE STROMAL VACULAR FRACTION; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BEHAVIOR; CENTRAL NERVOUS TISSUE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GRANULOCYTE; HELPER CELL; HEMATOPOIETIC CELL; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPH NODE; LYMPHOID ORGAN; MACROPHAGE; MAST CELL; MOTOR PERFORMANCE; MOUSE; MULTIPLE SCLEROSIS; MURINE MODEL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SMOOTH MUSCLE CELL; SPINAL CORD; STEM CELL TRANSPLANTATION; STROMA CELL; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; BLOOD; C57BL MOUSE; CELL COUNT; CYTOLOGY; DISEASE EXACERBATION; DISEASE MODEL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LYMPHOID TISSUE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PHENOTYPE;

ADIPOSE TISSUE; ANIMALS; BLOOD PROTEINS; CELL COUNT; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOMODULATION; INFLAMMATION MEDIATORS; LYMPHOID TISSUE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; PHENOTYPE; SPINAL CORD; STROMAL CELLS;

EID: 85000900114     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2516     Document Type: Article

References (46)

1. Dulamea A. Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. J Med Life 2015;8:24–27.
2. Fletcher JM, Lalor SJ, Sweeney CM et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010;162:1–11.
3. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953–1971.
4. Constantinescu CS, Farooqi N, O'Brien K et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 2011;164:1079–1106.
5. Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001;7:211–228.
6. Aust L, Devlin B, Foster SJ et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 2004;6:7–14.
7. Semon JA, Zhang X, Pandey AC et al. Administration of murine stromal vascular fraction ameliorates chronic experimental autoimmune encephalomyelitis. Stem Cells Transl Med 2013;2:789–796.
8. Yoshimura K, Sato K, Aoi N et al. Cell-assisted lipotransfer for facial lipoatrophy: Efficacy of clinical use of adipose-derived stem cells. Dermatol Surg 2008;34:1178–1185.
9. Astori G, Vignati F, Bardelli S et al. “In vitro” and multicolor phenotypic characterization of cell subpopulations identified in fresh human adipose tissue stromal vascular fraction and in the derived mesenchymal stem cells. J Transl Med 2007;5:55.
10. Zuk PA, Zhu M, Ashjian P et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279–4295.
11. Berg J, Roch M, Altschuler J et al. Human adipose-derived mesenchymal stem cells improve motor functions and are neuroprotective in the 6-hydroxydopamine-rat model for Parkinson's disease when cultured in monolayer cultures but suppress hippocampal neurogenesis and hippocampal memory function when cultured in spheroids. Stem Cell Rev 2015;11:133–149.
12. Ghasemi N. Therapeutic effects of adipose derived mesenchymal stem cells on remyelination process in inflammatory demyelinating diseases. J Histol Histopathol 2015;2:8.
13. Kang SK, Jun ES, Bae YC et al. Interactions between human adipose stromal cells and mouse neural stem cells in vitro. Brain Res Dev Brain Res 2003;145:141–149.
14. Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929–939.
15. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009;60:1006–1019.
16. Franquesa M, Mensah FK, Huizinga R et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 2015;33:880–891.
17. Yoshimura K, Sato K, Aoi N et al. Cell-assisted lipotransfer for cosmetic breast augmentation: Supportive use of adipose-derived stem/stromal cells. Aesthetic Plast Surg 2008;32:48–55. discussion 56-7.
18. Zhu M, Zhou Z, Chen Y et al. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg 2010;64:222–228.
19. Black LL, Gaynor J, Gahring D et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: A randomized, double-blinded, multicenter, controlled trial. Vet Ther 2007;8:272–284.
20. Black LL, Gaynor J, Adams C et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008;9:192–200.
21. Vilar JM, Batista M, Morales M et al. Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis. BMC Vet Res 2014;10:143.
22. Fortier LA, Potter HG, Rickey EJ et al. Concentrated bone marrow aspirate improves full-thickness cartilage repair compared with microfracture in the equine model. J Bone Joint Surg Am 2010;92:1927–1937.
23. Semon JA, Maness C, Zhang X et al. Comparison of human adult stem cells from adipose tissue and bone marrow in the treatment of experimental autoimmune encephalomyelitis. Stem Cell Res Ther 2014;5:2.
24. Scruggs BA, Semon JA, Zhang X et al. Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model. Stem Cells Transl Med 2013;2:797–807.,
25. Strong AL, Bowles AC, Wise RM et al. Human adipose stromal/stem cells from obese donors show reduced efficacy in halting disease progression in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Stem Cells 2016;34: 614–626.
26. Ripoll CB, Bunnell BA. Comparative characterization of mesenchymal stem cells from eGFP transgenic and non-transgenic mice. BMC Cell Biol 2009;10:3.
27. Scruggs BA, Bowles AC, Zhang X et al. High-throughput screening of stem cell therapy for globoid cell leukodystrophy using automated neurophenotyping of twitcher mice. Behav Brain Res 2013;236:35–47.
28. Duhen R, Glatigny S, Arbelaez CA et al. Cutting edge: The pathogenicity of IFN-gamma-producing Th17 cells is independent of T-bet. J Immunol 2013;190:4478–4482.
29. Jager A, Dardalhon V, Sobel RA et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009;183:7169–7177.
30. Chaudhry A, Samstein RM, Treuting P et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011;34:566–578.
31. Zhang X, Koldzic DN, Izikson L et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004;16:249–256.
32. Ludviksson BR, Seegers D, Resnick AS et al. The effect of TGF-beta1 on immune responses of naive versus memory CD4+ Th1/Th2 T cells. Eur J Immunol 2000;30:2101–2111.
33. Wang Z, Hong J, Sun W et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006;116:2434–2441.
34. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755–1761.
35. Kohm AP, Carpentier PA, Miller SD. Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+CD25+ regulatory T cells. Novartis Found Symp 2003;252:45–52; discussion 52-4, 106-14.
36. Abrahamsson SV, Angelini DF, Dubinsky AN et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 2013;136:2888–2903.
37. Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011;11:1295–1303.
38. Darlington PJ, Touil T, Doucet JS et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341–354.
39. Park KH, Mun CH, Kang MI et al. Treatment of collagen-induced arthritis using immune modulatory properties of human mesenchymal stem cells. Cell Transplant 2016;25:1057–1072.
40. Cho KS, Park MK, Kang SA et al. Adipose-derived stem cells ameliorate allergic airway inflammation by inducing regulatory T cells in a mouse model of asthma. Mediators Inflamm 2014;2014:436476.
41. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35.
42. Rath M, Muller I, Kropf P et al. Metabolism via Arginase or nitric oxide synthase: Two Competing arginine pathways in macrophages. Front Immunol 2014;5:532.
43. Weisser SB, McLarren KW, Kuroda E et al. Generation and characterization of murine alternatively activated macrophages. Methods Mol Biol 2013;946:225–239.
44. Liu C, Li Y, Yu J et al. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 2013;8:e54841.
45. Mikita J, Dubourdieu-Cassagno N, Deloire MS et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 2011;17:2–15.
46. Doi K, Tanaka S, Iida H et al. Stromal vascular fraction isolated from lipo-aspirates using an automated processing system: Bench and bed analysis. J Tissue Eng Regen Med 2013;7:864–870.